The 36-month beta value for ABUS is at 1.93. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ABUS is 147.08M, and currently, shorts hold a 4.57% of that float. The average trading volume for ABUS on February 25, 2025 was 770.56K shares.
ABUS) stock’s latest price update
Arbutus Biopharma Corp (NASDAQ: ABUS)’s stock price has increased by 7.78 compared to its previous closing price of 3.34. However, the company has seen a 7.14% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-25 that WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D.
ABUS’s Market Performance
ABUS’s stock has risen by 7.14% in the past week, with a monthly rise of 8.43% and a quarterly rise of 4.65%. The volatility ratio for the week is 3.16% while the volatility levels for the last 30 days are 3.64% for Arbutus Biopharma Corp The simple moving average for the last 20 days is 6.63% for ABUS stock, with a simple moving average of 0.82% for the last 200 days.
Analysts’ Opinion of ABUS
Many brokerage firms have already submitted their reports for ABUS stocks, with Jefferies repeating the rating for ABUS by listing it as a “Buy.” The predicted price for ABUS in the upcoming period, according to Jefferies is $5 based on the research report published on February 02, 2022 of the previous year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $5. The rating they have provided for ABUS stocks is “Hold” according to the report published on February 25th, 2021.
H.C. Wainwright gave a rating of “Buy” to ABUS, setting the target price at $10 in the report published on December 17th of the previous year.
ABUS Trading at 7.88% from the 50-Day Moving Average
After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.81% of loss for the given period.
Volatility was left at 3.64%, however, over the last 30 days, the volatility rate increased by 3.16%, as shares surge +5.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.86% lower at present.
During the last 5 trading sessions, ABUS rose by +7.59%, which changed the moving average for the period of 200-days by +27.29% in comparison to the 20-day moving average, which settled at $3.38. In addition, Arbutus Biopharma Corp saw 10.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABUS starting from HASTINGS DAVID C, who sale 22,183 shares at the price of $3.28 back on Feb 04 ’25. After this action, HASTINGS DAVID C now owns 159,724 shares of Arbutus Biopharma Corp, valued at $72,827 using the latest closing price.
Sims Karen, the Chief Medical Officer of Arbutus Biopharma Corp, sale 19,348 shares at $3.28 during a trade that took place back on Feb 04 ’25, which means that Sims Karen is holding 106,194 shares at $63,519 based on the most recent closing price.
Stock Fundamentals for ABUS
Current profitability levels for the company are sitting at:
- -12.24 for the present operating margin
- 0.84 for the gross margin
The net margin for Arbutus Biopharma Corp stands at -11.38. The total capital return value is set at -0.68. Equity return is now at value -67.81, with -51.29 for asset returns.
Based on Arbutus Biopharma Corp (ABUS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -48.77. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -546.46.
Currently, EBITDA for the company is -70.99 million with net debt to EBITDA at 0.4. When we switch over and look at the enterprise to sales, we see a ratio of 96.25. The receivables turnover for the company is 4.19for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.02.
Conclusion
In conclusion, Arbutus Biopharma Corp (ABUS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
